Generation Bio Co. (NASDAQ:GBIO) Given Average Rating of “Hold” by Brokerages

Shares of Generation Bio Co. (NASDAQ:GBIO) have earned an average rating of “Hold” from the seven research firms that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $8.8750.

GBIO has been the subject of several recent analyst reports. Zacks Research raised shares of Generation Bio to a “hold” rating in a report on Monday, January 26th. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Generation Bio in a research note on Friday, November 7th. Wedbush set a $5.50 target price on Generation Bio and gave the stock an “outperform” rating in a research report on Tuesday, December 16th. Citigroup reissued a “market perform” rating on shares of Generation Bio in a report on Wednesday, December 17th. Finally, Jefferies Financial Group lowered shares of Generation Bio from a “buy” rating to a “hold” rating and cut their price objective for the company from $11.00 to $5.00 in a report on Tuesday, December 16th.

Generation Bio Trading Up 1.1%

Generation Bio stock opened at $5.70 on Wednesday. Generation Bio has a 12-month low of $3.00 and a 12-month high of $8.42. The firm has a market capitalization of $38.42 million, a price-to-earnings ratio of -0.61 and a beta of 2.05. The firm has a 50 day moving average of $5.49 and a 200 day moving average of $5.58.

Generation Bio (NASDAQ:GBIO) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.82) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.18) by $2.36. The business had revenue of $1.59 million during the quarter, compared to analyst estimates of $0.66 million. Generation Bio had a negative net margin of 410.13% and a negative return on equity of 94.82%. On average, analysts predict that Generation Bio will post -1.75 EPS for the current year.

Institutional Trading of Generation Bio

A number of institutional investors and hedge funds have recently bought and sold shares of GBIO. Acadian Asset Management LLC lifted its stake in Generation Bio by 54.3% in the 1st quarter. Acadian Asset Management LLC now owns 1,159,135 shares of the company’s stock worth $468,000 after purchasing an additional 407,843 shares in the last quarter. Militia Capital Partners LP purchased a new stake in shares of Generation Bio in the second quarter worth about $174,000. Y Intercept Hong Kong Ltd purchased a new stake in shares of Generation Bio in the second quarter worth about $47,000. Marshall Wace LLP bought a new position in Generation Bio during the second quarter valued at approximately $37,000. Finally, Cantor Fitzgerald L. P. purchased a new position in Generation Bio during the 3rd quarter valued at approximately $606,000. 95.22% of the stock is currently owned by institutional investors.

About Generation Bio

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.